Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813936 | 0.98 | CYP2A13 (0.96) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL11193326 | 0.86 | CYP2A13 (0.75) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL1927702 | 0.83 | CYP2A13 (0.71) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL18190587 | 0.83 | CYP2A13 (0.71) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL7447200 | 0.82 | CYP2A13 (0.70) | CYP2A13ALDH1A1CYP2C9ATMTSHR | |
| SCHEMBL6228351 | 0.82 | CYP2A13 (0.70) | CYP2A13ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL18356563 | 0.81 | ALDH1A1 (0.71) | CYP2A13ALDH1A1CYP2C9ATMTSHR | |
| SCHEMBL6818375 | 0.79 | ALDH1A1 (0.69) | CYP2A13ALDH1A1CYP2C9ATMTSHR | |
| SCHEMBL8162127 | 0.79 | KDM4E (0.66) | CYP2A13ALDH1A1KMT2AMEN1ATM | |
| SCHEMBL4764209 | 0.78 | CYP2A13 (0.64) | CYP2A13ALDH1A1ATMTSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598165-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2013-12-03 | — | — | US | claimed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | claimed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2014146246-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-8598165-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2013-12-03 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | CYP2A13 2520/4885ALDH1A1 2989/4885CYP2C9 2491/4885 |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | CYP1A2, CYP2D6, CYP1A1 | CYP2A13 6/4885ALDH1A1 120/4885CYP2C9 28/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | CYP2A13 4434/4885ALDH1A1 4638/4885CYP2C9 4692/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | CYP2A13 3380/4885ALDH1A1 1071/4885CYP2C9 2660/4885 |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | CYP1A2, CYP2D6, CYP1A1 | CYP2A13 6/4885ALDH1A1 120/4885CYP2C9 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.